EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development

(2018) Zev A. Binder et al.   CANCER CELL

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

OS11.5 ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma

(2017) M. Weller et al.   NEURO-ONCOLOGY

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma

(2017) Stephan Arni et al.   Oncotarget

Clustered localization of EGFRvIII in glioblastoma cells as detected by high precision localization microscopy

(2016) Philip S. Boyd et al.   Nanoscale

Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines

(2016) Matthias Riedel et al.   Oncotarget

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide

(2015) J. L. McFaline-Figueroa et al.   CANCER RESEARCH

EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide

(2015) Manuela Cominelli et al.   JNCI-Journal of the National Cancer Institute

Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas

(2015) Martin J. van den Bent et al.   NEURO-ONCOLOGY

Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest

(2015) Malte Kriegs et al.   RADIOTHERAPY AND ONCOLOGY

EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells

(2015) Nina Struve et al.   Oncotarget

EGFR Amplified and Overexpressing Glioblastomas and Association With Better Response to Adjuvant Metronomic Temozolomide

(2015) Manuela Cominelli et al.   JNCI-Journal of the National Cancer Institute

Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited

(2015) Nicola Montano et al.   NEOPLASIA

EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

(2014) Claire Faulkner et al.   BRITISH JOURNAL OF NEUROSURGERY

JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma

(2014) Q. Zheng et al.   NEURO-ONCOLOGY

EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma

(2013) Qi-Wen Fan et al.   CANCER CELL

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

(2013) Michael Weller et al.   INTERNATIONAL JOURNAL OF CANCER

Early Chk1 Phosphorylation Is Driven by Temozolomide-Induced, DNA Double Strand Break- and Mismatch Repair-Independent DNA Damage

(2013) Motokazu Ito et al.   PLoS One

Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients

(2013) Michał Bieńkowski et al.   PLoS One

Epidermal Growth Factor Receptor Mutation Status and Rad51 Determine the Response of Glioblastoma to Multimodality Therapy with Cetuximab, Temozolomide, and Radiation

(2013) Phyllis Rachelle Wachsberger et al.   Frontiers in Oncology

Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas

(2012) Gordon Li et al.   JOURNAL OF NEURO-ONCOLOGY

Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles

(2011) Steve Quiros et al.   CELL CYCLE

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma

(2009) B. Mukherjee et al.   CANCER RESEARCH

The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation

(2009) J. Portnow et al.   CLINICAL CANCER RESEARCH

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY